Theradiag SA (ALTHE) - Cash Flow Conversion Efficiency

Latest as of June 2025: 1.404x

Based on the latest financial reports, Theradiag SA (ALTHE) has a cash flow conversion efficiency ratio of 1.404x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.56 Million ≈ $-4.17 Million USD) by net assets (€-2.54 Million ≈ $-2.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Theradiag SA's balance sheet to measure how much of total assets are equity-financed.

Theradiag SA - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Theradiag SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Theradiag SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Theradiag SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Theradiag SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Veru Inc NASDAQ:VERU	-0.166x
DynaCERT Inc. TO:DYA	2.389x
Memscap Regpt PA:MEMS	0.048x
Cyclone Metals Ltd AU:CLE	-0.088x
City Of London Investment Trust LSE:CTY	0.005x
Baan Rock Garden Public Company Limited BK:BROCK	0.001x
Bridgepoint Group Plc LSE:BPT	0.015x
Black Canyon Ltd AU:BCA	-0.044x

Annual Cash Flow Conversion Efficiency for Theradiag SA (2011–2024)

The table below shows the annual cash flow conversion efficiency of Theradiag SA from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see ALTHE company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€-114.00 ≈ $-133.28	€-2.91 Million ≈ $-3.40 Million	25535.088x	+5810417.91%
2023-12-31	€5.65 Million ≈ $6.61 Million	€-2.48 Million ≈ $-2.90 Million	-0.439x	+95.45%
2022-12-31	€544.87K ≈ $637.01K	€-5.27 Million ≈ $-6.16 Million	-9.665x	-416.71%
2021-12-31	€-1.27 Million ≈ $-1.49 Million	€-3.88 Million ≈ $-4.54 Million	3.052x	+197.46%
2020-12-31	€-3.24 Million ≈ $-3.79 Million	€-3.32 Million ≈ $-3.88 Million	1.026x	-97.79%
2019-12-31	€-79.73K ≈ $-93.21K	€-3.69 Million ≈ $-4.32 Million	46.321x	+420.83%
2018-12-31	€-531.93K ≈ $-621.88K	€-4.73 Million ≈ $-5.53 Million	8.894x	+554.82%
2017-12-31	€3.47 Million ≈ $4.06 Million	€-6.79 Million ≈ $-7.93 Million	-1.955x	-37.04%
2016-12-31	€5.58 Million ≈ $6.53 Million	€-7.97 Million ≈ $-9.31 Million	-1.427x	+78.31%
2015-12-31	€756.80K ≈ $884.78K	€-4.98 Million ≈ $-5.82 Million	-6.579x	-252.44%
2014-12-31	€2.77 Million ≈ $3.24 Million	€-5.18 Million ≈ $-6.05 Million	-1.867x	-275.77%
2013-12-31	€-3.80 Million ≈ $-4.45 Million	€-4.04 Million ≈ $-4.72 Million	1.062x	+111.88%
2012-12-31	€297.60K ≈ $347.92K	€-2.66 Million ≈ $-3.11 Million	-8.938x	-13.01%
2011-12-31	€120.37K ≈ $140.73K	€-952.02K ≈ $-1.11 Million	-7.909x	--

About Theradiag SA

PA:ALTHE France Medical Devices

Market Cap

$43.58 Million

€37.28 Million EUR

Market Cap Rank

#23035 Global

#363 in France

Share Price

€0.63

Change (1 day)

+7.50%

52-Week Range

€0.43 - €0.87

All Time High

€8.20